Lupin expects India sales to grow 18-20 pct in fiscal 2015; net profit jumps

Image
Reuters MUMBAI
Last Updated : Jul 30 2014 | 3:27 PM IST

By Zeba Siddiqui

MUMBAI (Reuters) - Drugmaker Lupin Ltd expects its local business to grow between 18 and 20 percent this fiscal year, its chief executive said, after higher sales in the domestic market helped it post a 56 percent jump in quarterly net profit.

India, which made up nearly a fourth of Lupin's total sales in the June quarter, was a drag on its earnings in January-March as many of the company's drugs fell under the federal government's price cap order of last year.

India sales grew 29 percent in the quarter ended June, its fiscal first quarter, the company said on Wednesday.

Lupin, India's fourth-largest generic drugmaker by sales, has been on the lookout for acquisitions that would enhance its branded generics business in the United States, its biggest market.

Lupin is one of several firms planning to bid for a portfolio of older drugs being auctioned by Britain's GlaxoSmithKline Plc , sources familiar with the matter told Reuters last week.

"We are continuously on the lookout for opportunities that enhance our technology capabilities," Chief Executive Vinita Gupta said. She declined to comment on the GlaxoSmithKline auction.

PROFIT BEATS ESTIMATES

Lupin reported a first-quarter net profit of 6.25 billion rupees ($103.92 million), compared with 4.01 billion rupees a year earlier. Analysts on average expected a profit of 5.10 billion rupees, according to Thomson Reuters data.

Net sales rose 36 percent to 32.84 billion rupees, helped largely by a 57 percent jump in its formulation business in the United States, which accounted for 49 percent of its sales in the June quarter.

Rival Dr Reddy's Laboratories Ltd , India's No.2 drugmaker by sales, on Wednesday reported a 52 percent jump in net profit to 5.5 billion rupees, in line with estimates, as its North American sales rose 51 percent in the June quarter.

Lupin's shares were up 4.5 percent at 1,169.35 rupees at 0935 GMT, while those of Dr Reddy's were up 1.7 percent at 2,817.20 rupees. The Nifty was up 0.5 percent.

($1 = 60.14 rupees)

(Editing by Sumeet Chatterjee and Matt Driskill)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 30 2014 | 3:21 PM IST

Next Story